Blood RNA Test Predicts Breast Cancer Immunotherapy Response Without Biopsy
A blood-based immune biomarker predicts which breast cancer patients will respond to checkpoint immunotherapy, validated across two independent cohorts.
Summary
Researchers developed a blood test using RNA sequencing that can predict how breast cancer patients will respond to immunotherapy — without invasive tumor biopsies. Analyzing 546 blood samples from 160 patients with high-risk breast cancer, they found that early responders to chemoimmunotherapy had high baseline immune cell diversity that rapidly expanded after just one treatment cycle. They built a multiparametric immune biomarker from these patterns and validated it in a separate group of 59 patients receiving a different immunotherapy drug. This approach could help oncologists personalize treatment decisions earlier, sparing non-responders from ineffective therapies and their side effects. The findings highlight peripheral blood as a practical, dynamic window into how the immune system is engaging with cancer treatment.
Detailed Summary
Predicting which cancer patients will benefit from immunotherapy remains one of oncology's most pressing challenges. Current methods often require repeated tumor biopsies — invasive, costly, and not always feasible — leaving clinicians with limited real-time insight into treatment response. A blood-based alternative could transform how oncologists monitor and adjust therapy.
This study performed RNA sequencing on 546 peripheral blood samples collected from 160 patients with high-risk stage II/III HER2-negative breast cancer enrolled in a clinical trial. Patients received either chemotherapy alone or chemotherapy combined with the checkpoint inhibitor pembrolizumab. The researchers analyzed immune gene expression patterns across tumor subtypes and treatment timepoints.
Key findings revealed that patients with triple-negative breast cancer showed elevated T cell receptor clonality and stronger immune activation signatures in blood compared to other subtypes. Among patients receiving chemoimmunotherapy, those who ultimately responded showed high baseline T cell receptor diversity, followed by rapid clonal expansion after just one treatment cycle — a dynamic pattern distinguishable early in the course of therapy.
Building on these observations, the team developed a multiparametric peripheral immune biomarker integrating baseline and early on-treatment blood features. This biomarker successfully predicted response to pembrolizumab and was independently validated in a cohort of 59 patients treated with dostarlimab, a different PD-1 inhibitor, strengthening its generalizability across checkpoint therapies.
The clinical implications are significant. A validated blood-based test could enable oncologists to identify non-responders after just one cycle, allowing earlier treatment pivots and reducing unnecessary toxicity. For the longevity-minded clinician, this research also underscores the systemic immune landscape as a measurable, dynamic indicator of cancer biology. Caveats include the abstract-only basis of this summary and the need for prospective validation before clinical adoption.
Key Findings
- Blood RNA sequencing predicted breast cancer subtype and immunotherapy response without tumor biopsy.
- Early responders showed high baseline T cell diversity followed by rapid clonal expansion after one treatment cycle.
- Triple-negative breast cancer patients had elevated T cell receptor clonality in peripheral blood.
- A multiparametric blood biomarker validated across two independent cohorts and two different PD-1 inhibitors.
- Approach could enable treatment pivots after just one cycle, reducing unnecessary immunotherapy exposure.
Methodology
Prospective study analyzing 546 peripheral blood RNA sequencing samples from 160 patients with high-risk stage II/III HER2-negative breast cancer receiving chemotherapy with or without pembrolizumab. The predictive biomarker was independently validated in a separate cohort of 59 patients treated with dostarlimab. Multiparametric modeling integrated baseline and early on-treatment immune features.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access, limiting assessment of statistical methods, cohort characteristics, and biomarker specifics. The study requires prospective validation in larger, more diverse populations before clinical implementation. Generalizability beyond HER2-negative breast cancer and PD-1 inhibitors remains to be established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.